(Reuters) – The $26,500-per-year price tag for Eisai Co Ltd and Biogen Inc’s newly approved Alzheimer’s disease drug is slightly above expectations, but should not dent demand for the promising …
Tag:
biogen’s
-
-
– Biogen Inc said on Monday its research chief Alfred Sandrock, who led development of its Alzheimer’s disease drug Aduhelm, is leaving the company after a 23-year run. The company …